Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3103-3110

  Windt, Willemijn A K M ^a   Henning, Robert H ^a   Kluppel, Alex C A ^a   Xu, Ying ^a   De Zeeuw, Dick ^a   Van Dokkum, Richard P E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

5 6 nephrectomy; ACEi therapy; Cardiorenal interaction; Myocardial infarction

Indexed keywords

LISINOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; HEART INFARCTION; HEMODYNAMICS; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SURVIVAL RATE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CREATININE; HEMODYNAMICS; KIDNEY FAILURE; LISINOPRIL; MALE; MYOCARDIAL INFARCTION; NEPHRECTOMY; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 52449095604     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn233     Document Type: Article

References (38)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
2. Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678
3. van Dokkum RP, Eijkelkamp WB, Kluppel AC et al. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 2004; 15: 3103-3110
4. Jose P, Skali H, Anavekar N et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephtol 2006; 17: 2886-2891
5. Bongartz LG, Cramer MJ, Doevendans PA et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26: 11-17
6. Swedberg K, Eneroth P, Kjekshus J et al. CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736
7. Remuzzi G, Perico N, Macia M et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 99: S57-S65
8. Dikow R, Kihm LP, Zeier M et al. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004; 15: 1530-1536
9. Raine AE, Seymour AM, Roberts AF et al. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993; 92: 2934-2940
10. Amann K, Buzello M, Simonaviciene A et al. Capillary/myocyte mismatch in the heart in renal failure - a role for erythropoietin? Nephrol Dial Transplant 2000; 15: 964-969
11. Amann K, Tyralla K, Gross ML et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 2003; 63: 1708-1713
12. Mann JF, Gerstein HC, Yi QL et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641-647
13. Hillege HL, Fidler V, Diercks GFet al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
14. Windt WA, Eijkelkamp WB, Henning RH et al. Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosteronesystem intervention. J Am Soc Nephtol 2006; 17: 3059-3066
15. Leenen FH, Skarda V, Yuan B et al. Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am J Physiol 1999; 276: H317-H325
16. Schoemaker RG, Debets JJ, Struyker-Boudier HA et al. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. JMol Cell Cardiol 1991; 23: 187-197
17. Johnston KM, MacLeod BA, Walker MJ. Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Pharmacol 1983; 61: 1340-1353
18. Leenen FH, Skarda V, Yuan B et al. Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am J Physiol 1999; 276: H317-H325
19. Schoemaker RG, Debets JJ, Struyker-Boudier HA et al. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. JMol Cell Cardiol 1991; 23: 187-197
20. Johnston KM, MacLeod BA, Walker MJ. Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Pharmacol 1983; 61: 1340-1353
21. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
22. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. Kidney Int 2002; 62: 1402-1407
23. Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526
24. Janssen WM, Hillege H, Pinto-Sietsma SJ et al. Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. Clin Chem Lab Med 2000; 38: 1107-1110
25. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927
26. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295
27. Eijkelkamp WB, Hillege H, de Graeff PA et al. Effect of first myocardial ischemic event on renal function. Am J Cardiol 2007; 100: 7-12
28. Westendorp B, Schoemaker RG, Van Gilst WH et al. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril. Eur J Pharmacol 2005; 527: 141-149
29. Rambausek M, Ritz E, Mall G et al. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 1985; 28: 775-782
30. Mall G, Rambausek M, Neumeister A et al. Myocardial interstitial fibrosis in experimental uremia - implications for cardiac compliance. Kidney Int 1988; 33: 804-811
31. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-1285
32. Amann K, Wiest G, Zimmer G et al. Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992; 42: 1079-1085
33. Buzello M, Boehm C, Orth S et al. Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension. Virchows Arch 2003; 442: 364-371
34. Mento PF, Maita ME, Wilkes BM. Renal hemodynamics in rats with myocardial infarction: selective antagonism of angiotensin receptor subtypes. Am J Physiol 1996; 271: H2306-H2312
35. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 2005; 16(Suppl 1): S58-S63
36. Boos CJ. Cardiovascular protection with ace inhibitors - more HOPE for EUROPA? Med Sci Monit 2004; 10: SR23-SR28
37. Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587-1592
38. Lee DS, Tu JV, Juurlink DN et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005; 294: 1240-1247